Skip to Content
Merck
All Photos(1)

Key Documents

S1200000

Spironolactone

European Pharmacopoeia (EP) Reference Standard

Synonym(s):

4-Pregnen-21-oic acid-17α-ol-3-one-7α-thiol γ-lactone 7-acetate, 7α-(Acetylthio)-17α-hydroxy-3-oxopregn-4-ene-21-carboxylic acid γ-lactone

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C24H32O4S
CAS Number:
Molecular Weight:
416.57
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

pharmaceutical primary standard

API family

spironolactone

manufacturer/tradename

EDQM

mp

207-208 °C (lit.)

application(s)

pharmaceutical (small molecule)

format

neat

SMILES string

CC(=O)S[C@@H]1CC2=CC(=O)CC[C@]2(C)[C@H]3CC[C@@]4(C)[C@@H](CC[C@@]45CCC(=O)O5)[C@H]13

InChI

1S/C24H32O4S/c1-14(25)29-19-13-15-12-16(26)4-8-22(15,2)17-5-9-23(3)18(21(17)19)6-10-24(23)11-7-20(27)28-24/h12,17-19,21H,4-11,13H2,1-3H3/t17-,18-,19+,21+,22-,23-,24+/m0/s1

InChI key

LXMSZDCAJNLERA-ZHYRCANASA-N

Gene Information

human ... NR3C2(4306)

Looking for similar products? Visit Product Comparison Guide

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Spironolactone EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Biochem/physiol Actions

Spironolactone is a competitive aldosterone receptor antagonist. Used as potassium sparing diuretic.

Packaging

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Other Notes

Sales restrictions may apply.

Pictograms

Health hazard

Signal Word

Danger

Hazard Statements

Hazard Classifications

Carc. 2 - Repr. 1B - STOT RE 2

Storage Class Code

6.1C - Combustible, acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Sorry, we don't have COAs for this product available online at this time.

If you need assistance, please contact Customer Support.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Christopher J A Neil et al.
JAMA, 310(2), 204-204 (2013-07-11)
D A Andreev et al.
Kardiologiia, 53(3), 94-96 (2013-04-04)
It is a case report of bleeding when using dabigatran in patient with renal failure caused by the concurrent use of spironolactone and angiotensin-converting enzyme (ACE) inhibitors. The patient (75 years old) at the decompensation of chronic heart failure in
Aldosterone inhibition in patients with heart failure with preserved ejection fraction.
Lars H Lund et al.
JAMA, 310(2), 205-205 (2013-07-11)
Adam D Karns et al.
Journal of clinical hypertension (Greenwich, Conn.), 15(3), 186-192 (2013-03-06)
Aldosterone inhibition with mineralcorticoid receptor antagonists (MRAs) is an effective treatment for resistant hypertension. Aldosterone synthase inhibitors (ASIs) are currently being investigated as a new therapeutic strategy to reduce aldosterone secretion from the adrenal gland. In this study, the efficacy
Prescrire international, 22(139), 148-149 (2013-07-20)
Still no randomised controlled trials versus spironolactone, but a prematurely terminated placebo-controlled trial with 2737 patients.

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service